Patents by Inventor Daniel W. Kung

Daniel W. Kung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diacylglycerol acyltransferase 2 inhibitors
    Patent number: 9296745
    Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: March 29, 2016
    Assignee: Pfizer Inc.
    Inventors: Kay Ahn, Markus Boehm, Shawn Cabral, Philip A. Carpino, Kentaro Futatsugi, David Hepworth, Daniel W. Kung, Suvi Orr, Jian Wang
  • DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS
    Publication number: 20150087585
    Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: March 26, 2013
    Publication date: March 26, 2015
    Applicant: PFIZER INC.
    Inventors: Kay Ahn, Markus Boehm, Shawn Cabral, Philip A. Carpino, Kentaro Futatsugi, David Hepworth, Daniel W. Kung, Suvi Orr, Jian Wang
  • 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES
    Publication number: 20140080756
    Abstract: The present invention provides a compound of Formula (I) a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 20, 2014
    Applicant: Pfizer Inc.
    Inventors: Samit K. Bhattacharya, Kimberly O. Cameron, Dilinie P. Fernando, Kim F. McClure, Daniel W. Kung, Allyn T. Londregan, Suvi T.M. Orr
  • 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives
    Patent number: 8609680
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: December 17, 2013
    Assignee: Pfizer Inc.
    Inventors: Samit K. Bhattacharya, Kimberly O. Cameron, Dilinie P. Fernando, Kim F. McClure, Daniel W. Kung, Allyn T. Londregan, Suvi T. M. Simila
  • 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES
    Publication number: 20110230461
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.
    Type: Application
    Filed: March 16, 2011
    Publication date: September 22, 2011
    Inventors: Samit K. Bhattacharya, Kimberly O. Cameron, Dilinie P. Fernando, Kim F. McClure, Daniel W. Kung, Allyn T. Londregan, Suvi T. M. Simila
  • Aminopyrazole derivatives as GSK-3 inhibitors
    Patent number: 7671072
    Abstract: The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R1, R2, and R3 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof in the treatment of, inter alia, conditions, diseases, and symptoms including, inter alia, Alzheimer's Disease, cancer, dementia, depression, diabetes, hair loss, schizophrenia, and stroke.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: March 2, 2010
    Assignee: Pfizer Inc.
    Inventors: John W. Benbow, Daniel W. Kung
  • Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors
    Patent number: 7300944
    Abstract: The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R1, R2 and R3 are as defined herein; pharmaceutical formulations thereof; and use thereof in the treatment of, inter alia, conditions, diseases, and symptoms such as bipolar disorder, diabetes, dementia, Alzheimer's Disease, stroke, schizophrenia, depression, hair loss, and cancer.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: November 27, 2007
    Assignee: Pfizer Inc.
    Inventors: Daniel W. Kung, Travis T. Wager
  • Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
    Patent number: 7202245
    Abstract: The present invention provides compounds of formula (I) the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein Ra, Rb, R1, and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: April 10, 2007
    Assignee: Pfizer Inc.
    Inventors: John W. Benbow, Margaret Y. Chu-Moyer, Daniel W. Kung
  • Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors
    Publication number: 20040266815
    Abstract: The present invention provides compounds of formula (I) 1
    Type: Application
    Filed: June 23, 2004
    Publication date: December 30, 2004
    Applicant: Pfizer Inc
    Inventors: Daniel W. Kung, Travis T. Wager
  • Saframycins, analogues and uses thereof
    Patent number: 6809099
    Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof. In another aspect, the present invention provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. In yet another aspect, the present invention provides methods for treating cancer comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: October 26, 2004
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Alleyn T. Plowright, Daniel W. Kung, Brian Lanman
  • Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
    Publication number: 20040192698
    Abstract: The present invention provides compounds of formula (I) 1
    Type: Application
    Filed: March 22, 2004
    Publication date: September 30, 2004
    Applicant: Pfizer Inc.
    Inventors: John W. Benbow, Margaret Y. Chu-Moyer, Daniel W. Kung
  • Saframycins, analogues and uses thereof
    Publication number: 20030008873
    Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof.
    Type: Application
    Filed: November 5, 2001
    Publication date: January 9, 2003
    Inventors: Andrew G Myers, Alleyn T. Plowright, Daniel W. Kung, Brian Lanman